BCHE and Alzheimer disease: It is worth noting that the cognitive improvement amplitude shown by the ADAS-Cog 14 scale (SMD = −1.06) was significantly higher than that of traditional cholinesterase inhibitors (usually 0.3–0.5), which is in line with the efficacy trend of Lecanemab in the Clarity AD study (van Dyck et al., 2023), indicating that disease-modifying treatment may break through the therapeutic bottleneck of symptomatic treatment.